PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2015Thrombosis and Haemostasis22 citations

Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does low-dose aspirin prevent vascular events in patients with type 2 diabetes mellitus?

Population

Patients with type 2 diabetes mellitus

Design

Review

Key result

Low-dose aspirin prophylaxis in patients with diabetes is associated with a non-significant decrease in the risk of vascular events, with variable response linked to platelet COX-1 turnover rates.

Authors

FSFrancesca SantilliPPPasquale PignatelliFVFrancesco Violi

Discussion

Loading...

Member takes

Overview

May inform COX-1 turnover-guided personalization; leaves open aspirin's role in diabetes primary prevention.

Structured PICO

Does low-dose aspirin prevent vascular events in patients with type 2 diabetes mellitus?

P
Population
Patients with type 2 diabetes mellitus
I
Intervention
Low-dose aspirin
O
Outcome
Vascular eventshard clinical

Understanding mechanisms of residual platelet hyper-reactivity, such as variable COX-1 turnover, may help personalize anti-platelet strategies for primary prevention in diabetes.

Limitations

  • Limited amount of available data precludes a precise estimate of the effect size
  • limited amount of available data precludes a precise estimate of the effect size

Cite This Study

Santilli et al. (2015) conducted a review in Type 2 diabetes mellitus. Low-dose aspirin was evaluated. Low-dose aspirin prophylaxis in patients with diabetes is associated with a non-significant decrease in the risk of vascular events, with variable response linked to platelet COX-1 turnover rates.

synapsesocial.com/papers/6a5bf4ad9ba431813273d68dhttps://doi.org/10.1160/th15-03-0202
View Full Paper
Ask AI
Bookmark
Share